These courses are intended for internal hospital staff.

Activity Description:

Given the rarity and heterogeneity of sarcoma cancers, there are limited treatment options for many patients and many treatments/drugs are given off label. Identifying targetable molecular alterations can open further treatment options for patients and potentially lead to better patient outcomes. However, it is important to take a multimodal approach and have detailed discussions regarding discordant pathology results such that the group can reach consensus on what treatment(s) to proceed with for optimal patient outcomes. It is also crucial that decisions and outcomes be tracked so that positive outcomes/results can be reproduced for future patients with similar disease characteristics. There are several journal articles and good clinical evidence supporting the benefits of multimodal tumor boards including data showing that molecular tumor boards for sarcoma specifically can improve patient outcomes.

Target Audience:

Medical Oncologists, Radiation Oncologists, General Surgeons, Pathologists, Radiologists, Pharmacists, Nurses, Social Workers, Radiologic Technologists, Patient Care Facilitators and all Personnel involved in the care of the hematology cancer patient.

Learning Objectives:

At the conclusion of this Regularly Scheduled Series, participants should be able to:

1. Identify discordant, complex, or rare molecular and histopathological findings and describe how these findings may impact treatment approach.
2. Review therapeutic agents and treatment strategies and incorporate these into management of sarcoma patients discussed, including on-label, new/emerging, clinical trial, and off-label options where clinically indicated.
3. Improve communication and the collaborative performance of the multidisciplinary oncology care team in the management of sarcoma patients

Moderator:

Daniel Lerman, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.